Table 1 Baseline stroke risk stratification and recommended antithrombotic therapy for patients with nonvalvular atrial fibrillation
Strata | Clinical factors | Estimated bi-annual stroke risk (%) | 2001 ACCP recommended therapy [5] |
|---|---|---|---|
Low | Age < 65 years, no history of hypertension, heart failure or reduced LVEF, or prior systemic emboli | 2 | ASA |
Moderate-low | Age 65–75 years, no history of hypertension, heart failure or reduced LVEF, or prior systemic emboli | 4 | ASA or warfarin |
Moderate-high | Age 65–75 years, no history of hypertension, heart failure or reduced LVEF, or prior systemic emboli but have diabetes mellitus or coronary artery disease | 6 | Warfarin (target INR 2–3) |
High | Age ≤ 75 years with history of hypertension or heart failure/reduced LVEF OR age > 75 years with no history of hypertension, heart failure or reduced LVEF, or prior systemic emboli | 12 | Warfarin (target INR 2–3) |
Very High | Age > 75 years with history of hypertension or heart failure/reduced LVEF OR any age with prior emboli | 20 | Warfarin (target INR 2–3) |